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Abstract
Acquired uniparental disomy (aUPD) is a common finding in myeloid
malignancies and typically acts to convert a somatically acquired heterozygous
mutation to homozygosity. We sought to identify the target of chromosome 14
aUPD (aUPD14), a recurrent abnormality in myeloid neoplasms and population
cohorts of elderly individuals. We identified 29 cases with aUPD14q that defined
a minimal affected region (MAR) of 11.2 Mb running from 14q32.12 to the
telomere. Exome sequencing (n=7) did not identify recurrently mutated genes,
but methylation-specific PCR at the imprinted MEG3-DLK1 locus located within
the MAR demonstrated loss of maternal chromosome 14 and gain of paternal
chromosome 14 (P<0.0001), with the degree of methylation imbalance correlating
with the level of aUPD (r=0.76; P=0.0001). The absence of driver gene mutations
in the exomes of three individuals with aUPD14q but no known haematological
disorder suggests that aUPD14q may be sufficient to drive clonal haemopoiesis.
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Profound parental bias associated with chromosome 14
acquired uniparental disomy indicates targeting of an
imprinted locus
A Chase1,2, W Leung1,2, W Tapper2, AV Jones1,2, L Knoops3, C Rasi4, LA Forsberg4, P Guglielmelli5, K Zoi6, V Hall1,2, L Chiecchio1,
L Eder-Azanza1, C Bryant1,2, L Lannfelt7, L Docherty1,2, HE White1,2, J Score1,2, DJG Mackay1,2, AM Vannucchi5, JP Dumanski4 and
NCP Cross1,2
Acquired uniparental disomy (aUPD) is a common ﬁnding in myeloid malignancies and typically acts to convert a somatically
acquired heterozygous mutation to homozygosity. We sought to identify the target of chromosome 14 aUPD (aUPD14), a recurrent
abnormality in myeloid neoplasms and population cohorts of elderly individuals. We identiﬁed 29 cases with aUPD14q that deﬁned
a minimal affected region (MAR) of 11.2 Mb running from 14q32.12 to the telomere. Exome sequencing (n= 7) did not identify
recurrently mutated genes, but methylation-speciﬁc PCR at the imprinted MEG3-DLK1 locus located within the MAR demonstrated
loss of maternal chromosome 14 and gain of paternal chromosome 14 (Po0.0001), with the degree of methylation imbalance
correlating with the level of aUPD (r= 0.76; P= 0.0001). The absence of driver gene mutations in the exomes of three individuals
with aUPD14q but no known haematological disorder suggests that aUPD14q may be sufﬁcient to drive clonal haemopoiesis.
Analysis of cases with both aUPD14q and JAK2 V617F (n= 11) indicated that aUPD14q may be an early event in some cases but a
late event in others. We conclude that aUPD14q is a recurrent abnormality that targets an imprinted locus and may promote clonal
haemopoiesis either as an initiating event or as a secondary change.
Leukemia (2015) 29, 2069–2074; doi:10.1038/leu.2015.130
INTRODUCTION
Uniparental disomy (UPD) refers to the situation in which both
copies of a chromosome pair or parts of chromosomes have
originated from one parent. Constitutional UPD is associated with
developmental disorders caused by the abnormal expression of
imprinted genes, that is, genes that are differentially expressed
depending on whether they have been maternally or paternally
inherited. By contrast, somatically acquired UPD (aUPD) in cancer
is a mechanism by which a pre-existing driver mutation (usually
somatically acquired) is converted to homozygosity, thereby
providing an additional clonal advantage. aUPD may involve
whole chromosomes as a result of non-disjunction or, more
commonly, whole chromosome arms or terminal segments as a
consequence of mitotic recombination. aUPD cannot be detected
by conventional cytogenetics but is readily apparent by the
ﬁnding of somatically acquired long homozygous tracts without
change in copy number by genome-wide single nucleotide
polymorphism (SNP) analysis.1
aUPD is prevalent in myeloid neoplasms: chromosomes 4q, 7q,
9p, 11q and 13q are commonly affected and target mutated TET2,
EZH2, JAK2, CBL and FLT3, respectively.1 Several other regions of
recurrent aUPD have been identiﬁed for which the target is
unknown, for example, chromosome 14q aUPD (aUPD14q) is seen
in myeloid neoplasms2 and is one of the most common
abnormalities associated with clonal haemopoiesis in population
cohorts of elderly individuals.3,4 Here we show an unexpected and
highly signiﬁcant parental bias associated with aUPD14q, implicat-
ing an imprinted locus at 14q32 as the primary target rather than
a speciﬁc mutated gene.
PATIENTS AND METHODS
Study cohorts
Our study comprised two major groups of individuals: (i) patients
diagnosed with a myeloproliferative neoplasm (MPN) or myelodysplastic
(MDS)/MPN according to standard morphological, haematologic and
laboratory criteria; (ii) population cohorts of elderly individuals from
Sweden, speciﬁcally the Uppsala Longitudinal Study of Adult Men5 and the
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS).6
The study was approved by the following ethics committees or review
boards: the National Research Ethics Service (UK) Committee South West,
the Uppsala Regional Ethical Review Board, the Ethics Committee of the
Biomedical Research Foundation of the Academy of Athens, Comitato
Etico, Azienda Ospedaliero-Universitaria Careggi, Firenze. Informed
consent was obtained according to the Declaration of Helsinki.
Molecular analysis
Genome wide SNP proﬁles for MPN and MDS/MPN cases, most of which
have been published previously,2,7 were obtained from peripheral blood or
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bone marrow leucocyte DNA using the Affymetrix SNP 6.0 (Affymetrix,
Santa Clara, CA, USA) or Illumina Human OmniExpressExome v1.2
platforms (Illumina, San Diego, CA, USA). Peripheral blood leucocyte
proﬁles for the Swedish population cohorts were obtained using Illumina
2.5M HumanOmni arrays (Illumina) have also been published.8 Exome
sequencing for MPN and MDS/MPN cases was performed using the Agilent
SureSelect kit (Agilent Technologies, Palo Alto, CA, USA) (Human All Exon
50Mb) and sequenced using an Illumina HiSeq 2000 (Illumina) at the
Wellcome Trust Centre for Human Genetics at Oxford, UK. Exome
sequencing for the Swedish cases was performed by SciLifeLab, Stockholm,
Sweden.
For methylation analysis, DNA was bisulphited (Zymo Research,
Ervine, CA, USA) alongside four healthy controls, ampliﬁed using
forward primers speciﬁc for methylated or unmethylated MEG3 or
NHP2L1 with a common FAM labelled reverse primer and analysed
with a 3130xl Genetic Analyser (Applied Biosystems, Foster City, CA, USA)
as described.9 Loss of heterozygosity analysis at 14q32 was performed
using microsatellites D14S553, D14S267, D14S1006, D14S542, D14S292
and D14S1007, again using a 3130xl Genetic Analyser. All primer
sequences are listed in Supplementary Table 1.
SNP array analysis
Array analysis was performed as described.7,10,11 For each SNP the log R
Ratio, a measure of normalised total signal intensity, and B Allele
Frequency (BAF), a measure of normalised allelic intensity ratio, were
determined using the BeadStudio (Illumina) and pennCNV12 software for
Illumina and Affymetrix arrays, respectively. Regions of aUPD were
identiﬁed by BAF segmentation10 which excluded non-informative SNPs
(SNPs with BAF40.9 or BAF o0.1 and SNPs where the absolute difference
in BAF between preceding and succeeding SNPs is40.6), mirrored BAF at
0.5 and used circular binary segmentation to identify regions with similar
allelic proportions. For heterozygous SNPs, the BAF is the proportion of the
total signal (A+B) accounted for by one allele (B). In a mixed population of
cells, the segmented mirrored BAF value will be a combination of values of
1 and 0.5 for cells with and without aUPD, respectively. Regions of aUPD
were therefore deﬁned as a region of allelic imbalance (segmented
mirrored BAF 40.56) with neutral copy number (log R ratio ~ 0) that
extended to the telomere.12 For samples with known JAK2 V617F levels,
determined by pyrosequencing,13 and BAF for both aUPD9p and aUPD14q
aUPD, we were able to calculate both the proportion of cells with aUPD14
and the proportion of cells which were homozygous or heterozygous for
JAK2 V617F. This allowed us to infer the likely order of acquisition
of aUPD14 and JAK2 V617F (see Supplementary Table 2 for detailed
calculations).
Sequence analysis
Analysis of exome sequencing data was as previously described.14 On
average, the targeted exome of chromosome 14 was sequenced to a
depth of 179× , and 94.3% of the target bases were covered by at least 20
reads (Supplementary Table 3). For variants passing quality control (read
depth ⩾ 4, alternate read depth ⩾ 2, phred scaled quality ⩾ 20, phred
scaled base call accuracy ⩾ 10, strand bias P⩾ 0.0001, base quality bias
P⩾ 1e-100, tail bias P⩾ 0.0001 and HWE P⩾ 0.0001), variant allele
frequencies were used to approximate BAF and were analysed accordingly
to conﬁrm regions of aUPD. The minimally affected region identiﬁed in
patient E5364 (chr14:94,245,652-qter) was interrogated in all aUPD14q
exomes for rare variants that were either novel or had a minor allele
frequency of ⩽ 1% in databases of common variation (1000 genomes,
Complete Genomics, Exome Variant Server).
RESULTS
Prevalence of aUPD14q
We analysed in house array data on cases with MPN or MDS/MPN
and identiﬁed aUPD14q extending to the 14q telomere in 25
cases. Of the UK cases (n= 21), 1/293 (0.3%) had MDS/MPN, 8/563
(1.6%) had JAK2 V617F negative MPN (7 CALR mutated; 1 MPL
mutated) and 12/1054 (1.1%) had JAK2 V617F positive MPN, an
overall prevalence similar to that identiﬁed in other studies of
myeloid neoplasms (8/498; 1.6%).2,7,15–17 Trisomy chromosome 14
(+14) was seen in 4/293 (1.4%) MDS/MPN cases.2 Of the 1641
individuals ⩾ 70 years of age in the Swedish population-based
cohorts, 4 (0.2%) had aUPD14,8 similar to the frequency in elderly
individuals reported by other larger studies of cases recruited for a
variety of genome-wide association studies.3,4 Cases with
aUPD14q or other chromosome 14 abnormalities in our study
are summarised in Table 1.
Minimally affected region
The region affected by aUPD14q was variable between individuals
and there was no difference between cases diagnosed with a
haematological malignancy and those picked up in population-
based screens (Figure 1). Since the boundary of our smallest
region of aUPD14q, case G_3499, was only deﬁned to the nearest
megabase, our minimally affected region was conservatively
deﬁned by case E5364 as 11.2 Mb running from 14q32.12 to the
telomere (chr14: 94,245,652-105,417,313). The minimal affected
region (MAR) in previously published analyses of genome-wide
association studies data was similar: 7.4 Mb (chr14: 98,962,371-
qter)4 and 6.9 Mb (chr14: 99,425,044-qter).3 This region does not
include FANCM, a variant of which was associated with aUPD14q
in a single case.18
Exome sequencing
Initially, with the aim of identifying a recurrently mutated
14q gene, we sequenced the whole exomes of cases with
aUPD14q (n= 7) or +14 (n= 1). We focused on the identiﬁcation
of novel variants in the minimal region of aUPD14q (chr14:
94,245,652-qter), thus capturing both constitutional and
somatic mutations that might provide a selective advantage
when reduced to homozygosity. No gene was identiﬁed with
likely causative variants in more than one individual
(Supplementary Table 3). In addition, no rare variants were
identiﬁed in FANCM which falls outside our MAR. Although it is
possible that a target gene might have been missed due to
inadequate coverage or mutational complexity, we considered
an alternative explanation.
Methylation bias associated with aUPD14q
Constitutional maternal UPD14q causes Temple syndrome,
whereas paternal UPD14q causes Kagami–Ogata syndrome. Both
are developmental conditions resulting from aberrant expression
of genes in the imprinted DLK1-MEG3 domain at 14q32. DLK1-
MEG3 is the only known imprinted locus on chromosome 14 and is
retained in the aUPD14q MAR deﬁned above. To test if DLK1-MEG3
might be targeted by chromosome 14 abnormalities, we
determined the MEG3 methylation status of cases with aUPD14q
(n= 22) or +14 (n= 6; Table 1). MEG3 is methylated on the
paternally inherited chromosome 14 but is unmethylated when
maternally inherited. An increase in methylation therefore
indicates paternal aUPD14q, that is, gain of the region containing
MEG3 from the paternal chromosome 14 and loss of the
corresponding region from the maternal chromosome 14
(Figure 2). Samples from cases with aUPD14q showed a striking
increase in methylation (mean methylation value 0.24, s.d. ± 0.17)
compared with healthy controls (n= 24; mean methylated value
0.00, s.d. ± 0.04) consistent with paternal aUPD (Figures 2a and b;
Mann–Whitney U-test, Po0.0001). Methylation values and BAF in
the region of aUPD14q were strongly correlated (Spearman’s rank
correlation, r= 0.76, P= 0.0001) (Figure 2), suggesting that the
relatively low levels of methylation imbalance in some individuals
was due to the presence of a small clone with aUPD14q. In
contrast, methylation in the +14 cases showed no parental bias
(mean methylation value 0.05, s.d. ± 0.17; +14 cases versus
controls, P= 0.34, Mann–Whitney U-test). This is the ﬁrst time to
our knowledge that aUPD has been associated with a speciﬁc
parent of origin effect, a ﬁnding that indicates that aUPD14q
targets an imprinted locus.
Parental bias associated with aUPD14
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Methylation bias is speciﬁc for aUPD14q
To determine if a parent of origin effect is seen in other regions of
aUPD, we analysed MDS/MPN cases with aUPD22q (n=5), an
abnormality that is also seen recurrently in myeloid malignancies
and population cohorts of elderly individuals. Like aUPD14q, the
target of aUPD22q has not been identiﬁed but there is a candidate
imprinted locus (NHP2L1) within the affected region.19 Methylation
analysis indicated maternal aUPD22q in two cases and paternal
aUPD22q in three cases (Supplementary Figure 1). Although the
number of cases is small, the ﬁndings clearly indicate no parent of
origin effect, supporting the notion that the imbalance observed for
aUPD14q is likely to be pathogenetically relevant.
Methylation bias in cases without aUPD14q
To determine if 14q imprinting abnormalities are more wide-
spread in myeloid neoplasia, MEG3 methylation status was
examined in additional MDS/MPN cases (n= 96) that had either
been analysed by SNP arrays and were known to be negative for
aUPD14q (n= 48) or were randomly selected without knowledge
of their aUPD14 status (n= 48). Most cases had methylation levels
Table 1. Summary of cases with chromosome 14 abnormalities
Patient
identiﬁer
aUPD14q region or karyotype (hg19 co-ordinates) aUPD14q
size (Mb)
Disorder Exome Driver mutations Mean B-allele
frequency of
aUPD14q region
Methylation
levela
E7173 chr14: 70924501-105930406 35.0 ET Yes SF3B1 K700E 0.81 0.45
E5364 chr14: 94245652-105417313 11.2 CMML Yes EZH2 exon9:
c.729-2A4-
0.91 0.49
E6459 chr14: 33291583-105930406 72.6 PMF Yes JAK2 V617F; TET2
D1242V
0.73 0.52
PT03B08 chr14:20211644-107285437 87.1 PMF — CALR Type 2 0.82 0.28
CB44 chr14:22053729-107285437 85.2 ET — CALR Type 1 0.74 0.05
PT02B05 chr14:73672831-107274052 33.6 ET — MPL W515K 0.8 0.25
PT02E11 chr14:23582569-107220898 83.6 ET — CALR Type 2 0.8 0.27
AN804 chr14:21240673-107285437 86.0 PMF — CALR Type 1 0.80 0.32
11_4629 chr14:21209871-107287663 86.1 ET — CALR Type 2 0.71 0.21
E6430 chr14:23102969-107274052 84.2 ET — CALR Type 1 0.64 0.12
E09853 chr14:20213937-107274052 87.1 PV — JAK2 V617F 0.62 − 0.10
E09861 chr14:20295510-107274052 87.0 PV — JAK2 V617F 0.77 0.19
E09895 chr14:56103882-107287663 51.1 PV — JAK2 V617F 0.71 0.22
E09984 chr14:50192257-107287663 57.1 ET — JAK2 V617F 0.79 0.31
H3589_11 chr14:59183573-107287663 48.1 PV — JAK2 V617F 0.58 0.07
H10872_10 chr14:24653187-107222493 82.6 PV — JAK2 V617F 0.58 0.12
W1212280 chr14:24843620-107287663 82.4 PV — JAK2 V617F 0.57 0.07
H131_12 chr14:92280675-107274052 15.0 PV — JAK2 V617F 0.63 0.07
PT1544 chr14: 94238353- 107287663 13.0 ET — CALR Type 2 0.69 ND
PT1645 chr14: 21070264- 105965102 84.9 ET — JAK2 V617F 0.89 ND
PT1670 chr14: 23248583- 107287663 84.0 ET — JAK2 V617F 0.79 ND
PT1876 chr14: 72220169- 107231967 35.0 ET — JAK2 V617F 0.89 ND
G_735 chr14:27349540-107349540 80b PMF — JAK2 V617F NA 0.40
G_3358 chr14:83349540-107349540 24b PMF — JAK2 V617F NA 0.52
G_3499 chr14:101250540-107349540 6b PMF — JAK2 V617F NA 0.19
ULSAM
546
chr14:24944467-107349540 82.4 PC Yes None detected 0.69 0.07
ULSAM
831
chr14:40334000-107349540 67.0 PC Yes None detected 0.67 ND
PIVUS 931 chr14:94156220-107331190 13.2 PC Yes JAK2 V617F; TP53
exon6:c.376-
2 A4G
0.77 ND
PIVUS 892 chr14:77435975-107349540 29.9 PC Yes None detected 0.61 ND
E4051 +14 — aCML Yes 0.15
E6901 +14 — CMML — − 0.14
W813483 46,XX,?dup(12)(p11p12),idic(14) (p11)/47,idem,+idic
(14)
— AML — 0.29
W1301891 47,XX,+14[20] — MDS — 0.12
W1407109 46,XX,del(5)(q13q33)[1]/58,sl,+1,+2,+del(5),+8,+9,
+10,+11,+13,+14,+19,+21,+22[9]/60,sdl1,+6,add(6)
(q1),+mar[2]
— MDS — 0.11
W1409489 45,X,-Y[6]/46,idem,+14[8]/46,XY[6] — MDS — −0.13
E7820 aUPD14q by microsatellite analysis — CMML — EZH2 C590F
Abbreviations: aCML, atypical chronic myeloid leukemia; AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; ET, essential
thrombocythemia; MDS, myelodysplastic syndrome; NA, not applicable; ND, not determined; PC, cases from Swedish elderly population-based cohorts
with no haematological malignancy diagnosed at the time of sampling (PIVUS 931 was subsequently diagnosed with polycythemia vera); PMF, primary
myeloﬁbrosis; PV, polycythemia vera. aPaternal chromosome loss or gain is given by the methylated (paternal) peak height divided by the sum of methylated
and unmethylated peaks, normalised to shift control values to zero. A positive value indicates methylation (paternal chromosome) gain compared with
controls. bRegions of aUPD14q only deﬁned to the nearest megabase, the minimally affected region of aUPD14q was therefore conservatively deﬁned by case
E5364 as 11.2 Mb, chr14: 94245652-qter.
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that were indistinguishable from healthy controls, but three had a
clear gain of methylation (Figure 2b). All three were of unknown
aUPD14q status and so we tested six microsatellite loci at 14q32:
only one case was homozygous at all six loci suggesting that gain
of methylation in the remaining two cases had arisen by a
mechanism other than aUPD14q (Supplementary Table 4).
EZH2 mutations in some cases with aUPD14q
MEG3 and other transcripts within the MEG3-DLK1 locus have been
implicated in regulation of the polycomb repressive complex 2
(PRC2),20 components of which are recurrently inactivated in
myeloid neoplasia by mutation of EZH2, SUZ12 or EED.2,21 It is
possible therefore that the consequence of aUPD14q might be
functional inactivation of PRC2, in which case we would expect
aUPD14q and PRC2 mutations to be mutually exclusive. Partial
sequence analysis of EZH2 and SUZ12, the most commonly
mutated components of PRC2, revealed causative EZH2 mutations
Methylated
(Paternal)
Unmethylated
(Maternal)
Control
No aUPD14q
aUPD14q
Paternal gain
Maternal loss
Figure 2. MEG3 methylation analysis. (a) PCR of bisulphited DNA allowed differential ampliﬁcation and relative quantiﬁcation of the
methylated (paternal) and unmethylated (maternal) alleles. Control samples show approximately equal paternal and maternal peak sizes,
whereas samples with a high level of aUPD14 show complete loss of the maternal allele. Methylation values are calculated as the methylated
paternal allele peak height divided by the sum of methylated and unmethylated peaks, with control values normalised to zero. Complete loss
of the maternal allele and gain of the paternal allele in cases is seen in cases with aUPD14q in the great majority of cells and is indicated by a
methylation value of 0.5. In many cases, aUPD14q is only seen in a proportion of cells, as indicated by the SNP array BAF in the affected region.
Consequently, the methylation value ranges between 0 and 0.5 for paternal gain/maternal loss and between 0 and − 0.5 for paternal
loss/maternal gain. (b) Methylation values for healthy controls (n= 24), cases with aUPD14q (n= 22), trisomy 14 (n= 6), randomly selected
MDS/MPN cases without knowledge of their aUPD14q status (n= 48) and MDS/MPN cases that were known to be negative for aUPD14q or
other visible chromosome 14 abnormalities (n= 48). The results show a highly signiﬁcant skewing (Po0.0001 Mann–Whitney U-test) in the
aUPD14q cases towards paternal aUPD. (c) Graph illustrating the strong correlation between the methylation value and mean aUPD BAF for
each case.
Pat expression
Mat expression
MEG3
DLK1 DIO3
miRNAssnoRNAs
MEG8
miRNAs
RTL1
R
eg
io
ns
 o
f a
U
PD
14
q
Chromosome 14
Myeloid 
neoplasia
Elderly 
cohort
q32
Figure 1. Extent of aUPD14q in the 29 cases, indicating the
minimally affected region and location of DLK1-MEG3.
Parental bias associated with aUPD14
A Chase et al
2072
Leukemia (2015) 2069 – 2074 © 2015 Macmillan Publishers Limited
in two out of eight aUPD14q cases (Supplementary Table 5), which
suggests that functional inactivation of PRC2 is unlikely to be the
primary consequence of aUPD14.
aUPD14q may be an early or late event
Inspection of the exome sequencing data for the aUPD14q cases
(n= 7) revealed no other obvious driver mutations in three out of
four individuals from the population cohorts, suggesting that
aUPD14q alone may be sufﬁcient to promote clonal haemopoiesis.
The fourth individual (PIVUS 931) was positive for JAK2 V617F as
well as a TP53 mutation; he was subsequently diagnosed with
polycythemia vera following recruitment into the PIVUS study. In
contrast, all three cases with diagnosed myeloid malignancy that
were exome sequenced had additional somatic driver mutations
in SF3B1, EZH2, JAK2 or TET2 (Table 1).
Of the aUPD14q cases that were positive for JAK2 V617F,
information on the mutation level as well as the BAF for 9p and
14q aUPD was available for 11 individuals. For these, we were able
to estimate both the proportion of cells with aUPD14q and the
proportion of cells which were homozygous or heterozygous for
JAK2 V617F (Figure 3). This in turn enabled us to infer whether
aUPD14q or JAK2 V617F was likely to have arisen ﬁrst. Assuming
that JAK2 V617F and aUPD14q arose within the same clone, our
ﬁndings suggest that aUPD14q arose before JAK2 V617F in cases
E09853, PT1645, PT1670 and PT1876 since the proportion of cells
positive for aUPD14q was twofold or higher than the proportion
positive for the JAK2 mutation. In contrast, JAK2 V617F is likely to
have arisen ﬁrst in cases E09861, H3589_11, H10872_10,
W1212280 H131_12 and E09984. The order is uncertain for case
E09895. It is notable therefore that aUPD14q arose ﬁrst in three
out of four cases with essential thrombocythemia but in only one
out of seven cases of polycythemia vera.
DISCUSSION
Developmental abnormalities arising from constitutional UPD
result from inappropriate expression of imprinted genes. Inherited
maternal UPD14q is associated with Temple Syndrome, character-
ized by low birth weight, hypotonia, motor delay, early onset of
puberty and short adult stature.22 Inherited paternal UPD14q is
associated with Kagami–Ogata syndrome, characterized by severe
developmental delay, hepatoblastoma and characteristic
dysmorphology.23 Both abnormalities result from aberrant expres-
sion of the DLK1-MEG3 domain at 14q32, a large and complex
imprinted cluster of genes and non-coding RNAs. The methylated
paternally derived chromosome expresses the protein-coding
genes DLK1, RTL1 and DIO3, while the non-methylated maternally
derived chromosome expresses the non-coding genes MEG3,
MEG8, asRTL1, multiple miRNAs and snoRNAs.24 It is not known
whether the observed clinical phenotypes are caused by aberrant
expression of an individual gene, individual non-coding RNAs or a
combination of factors.
Our ﬁnding of a highly signiﬁcant parent of origin effect
associated with aUPD14q strongly implicates an imprinted locus
as the primary target, and that paternal homozygosity for this
target provides a growth advantage over cells that harbour both
alleles. Del(20q), another somatic abnormality associated with
myeloid neoplasms, has been shown to target an imprinted gene
cluster25 but this is the ﬁrst time to our knowledge that aUPD has
been associated with an imprinted target. Although we cannot
exclude the possibility that aUPD14q might target another
imprinted locus at 14q32, we believe it is highly likely that the
true target is DLK1-MEG3 since (i) this cluster falls with the 11.2 Mb
MAR, an interval that contains 121 known protein-coding genes
plus the immunoglobulin region, and (ii) despite extensive
searches there are no other conﬁrmed imprinted loci within the
MAR, or indeed elsewhere on chromosome 14. Furthermore,
expression of DLK1-MEG3 has been reported to be deregulated in
diverse neoplasms in the absence of chromosome 14 abnormal-
ities, including acute promyelocytic leukaemia26,27 and
myeloﬁbrosis.28,29 In our study, we did not have suitably stored
material for expression analysis of aUPD14q cases; however,
expression analysis alone is unlikely to be informative since by
deﬁnition aUPD would be expected to distort the normal
expression of imprinted genes in the affected region whether
they were of pathogenetic relevance or not.
Of the 22 aUPD14q cases analysed for MEG3 methylation in our
study, 21 had positive values indicative of paternal aUPD. One
case had a negative methylation value. We do not have an
explanation for this aberrant case, but potentially other mutations
may have been present that promoted clonal expansion. We note
that aUPD for other regions has not been associated with a
speciﬁc mutational target in all cases, for example, we found that
only 9 of 12 MDS/MPN cases with aUPD7q had EZH2 mutations,
with the target of the remaining 3 cases remaining unclear.2
Similar to other mutations associated with clonal haemopoiesis
in population cohorts,30,31 aUPD14q is more prevalent in the
elderly. Previous studies found aUPD14q in 21/50 222 (0.04%)
individuals, rising to 14/15 101 (0.09%) in those 460 years of
age,3,4 an increase that parallels the increase in myeloid neoplasia
seen in the elderly. Analysis of longitudinal data estimated a
10-fold elevated risk of developing a haematological malignancy
for individuals with any acquired chromosome anomaly,4 and a
similar risk was estimated for individuals with somatic mutations
in genes known to be associated with myeloid malignancies.30,31
The most commonly mutated genes in population cohorts were
DNMT3A, TET2 and ASXL1, and the ﬁnding that most individuals
had only a single abnormality suggested that mutations in these
genes are often initiating events for clonal haemopoiesis.
Inspection of our exome sequencing data for the aUPD14q cases
revealed no mutations in known driver genes in three out of four
population cohort cases. By contrast, all three cases with
diagnosed myeloid malignancy had additional somatic driver
mutations. We suggest therefore that aUPD14q may also initiate
clonal haemopoiesis and predispose to overt malignancy. How-
ever, when we examined cases that had both aUPD14q and JAK2
V617F, it was clear that aUPD14q may be an early event in some
Figure 3. Proportions of cells positive for JAK2 V617F and aUPD14q
in cases with both abnormalities. Black bars indicate cells positive
for aUPD14q; grey bars indicate homozygous JAK2 V617F mutant
cells and white bars indicate heterozygous JAK2 V617F mutant cells.
Parental bias associated with aUPD14
A Chase et al
2073
© 2015 Macmillan Publishers Limited Leukemia (2015) 2069 – 2074
MPN cases but a late event in others. Furthermore, we found that
aUPD14q tends to arise before JAK2 V617F in essential thrombo-
cythaemia but after V617F in polycythemia vera. This is
reminiscent of the ﬁnding that mutated TET2 may precede or
follow the acquisition of JAK2 V617F in MPN, with the order of
acquisition inﬂuencing clinical features and stem cell biology.32
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